A new study published in Nature demonstrates that a gut infection can lead to a pathology resembling Parkinson鈥檚 disease (PD) in a mouse model lacking a gene linked to the human disease.
This discovery extends recent work by the same group suggesting that PD has a major immune component, providing new avenues for therapeutic strategies. The collaborative study was the work of a joint team of scientists led by Michel Desjardins and Louis-Eric Trudeau from University of Montreal, Heidi McBride at the Montreal Neurological Institute, and Samantha Gruenheid at 不良研究所.
The number of PD patients in the world more than doubled between 1990 and 2016, from 2.5M to 6.1M. A relatively conservative projected doubling of the number of patients over the next 30 years would yield more than 12 million patients worldwide by about 2050. About ten per cent of the cases of PD are due to mutations in genes coding for proteins such as PINK1 and Parkin, which have been linked to mitochondria (the organelle in cells that produces energy). Patients with these mutations develop PD at a much earlier age. However, in mouse models, the same mutations do not generate disease symptoms, leading many researchers to conclude that mice may not be suitable for the study of PD.
Trudeau and McBride, two specialists in the field of PD research, argue that the findings in this new study may explain this disparity: these animals are normally kept in germ-free facilities, conditions not representative of those encountered by human beings who are constantly exposed to infectious microorganisms. Gruenheid, a microbiologist, is confident that the link between infection and PD will stimulate the further study of the immune response linked to the initiation of the disease, allowing to develop and test novel therapeutic approaches.
PD is caused by the progressive death of a subset of neurons in the brain, called dopaminergic neurons. This loss of neurons is responsible for the typical motor symptoms observed in PD patients including tremors and rigidity. What causes the death of the dopaminergic neurons is still unknown. Trudeau, a neuroscientist, indicates that 鈥淢ost of the current models of PD are based on the belief that neurons die due to toxic elements accumulating inside them. This does not explain, however, the fact that PD pathology is initiated in patients several years before the emergence of the motor impairment and any noticeable loss of neurons鈥�. The reason for this is believed to be explained by the results of the present study. The Montreal team has shown that in mice lacking a gene linked to PD, infection with bacteria that cause mild intestinal symptoms in young mice was sufficient to trigger PD-like symptoms in these animals later in life.
The Parkinson鈥檚-like symptoms could be temporarily reversed by the administration of L-DOPA, a drug used to treat Parkinson鈥檚 patients. Desjardins and Diana Matheoud, an immunologist, point out that in normal mice, the immune system responded properly to the gut infection; however, in mice lacking the gene PINK1 related to Parkinson鈥檚, the immune system overreacted and triggered 鈥渁uto-immunity鈥�, a process that leads the immune system to attack healthy cells in the organism. The results published today suggest that rather than dying from toxin accumulation, the killing of dopaminergic neurons involves immune cells.
In the infected mutant mice, autoreactive toxic T lymphocytes were shown to be present in the brain and able to attack healthy neurons in culture dishes. The co-first authors on the published article, Matheoud and Tyler Cannon, a graduate student in microbiology, emphasize the fact that these results strongly suggest that some forms of PD are an autoimmune disease likely to start in the gut several years before patients notice any motor symptoms, highlighting the fact that a window of time exists for preventive treatment.
This exciting collaborative discovery required the expertise of a microbiologist, immunologist, neuroscientist and a cell biologist, highlighting the complexity of this devastating disease. Support for the work was provided through the Canadian Institutes of Health Research, the Brain Canada and Krembil Foundations and The Michael J. Fox Foundation for Parkinson鈥檚 Research.
Source:
